Zacks: Brokerages Anticipate Adaptimmune Therapeutics PLC (ADAP) to Post -$0.28 EPS
Wall Street brokerages predict that Adaptimmune Therapeutics PLC (NASDAQ:ADAP) will announce ($0.28) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Adaptimmune Therapeutics PLC’s earnings, with estimates ranging from ($0.30) to ($0.26). Adaptimmune Therapeutics PLC posted earnings of ($0.22) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 27.3%. The business is expected to announce its next quarterly earnings results on Monday, March 12th.
According to Zacks, analysts expect that Adaptimmune Therapeutics PLC will report full year earnings of ($0.82) per share for the current year, with EPS estimates ranging from ($1.08) to ($0.54). For the next year, analysts expect that the firm will report earnings of ($0.76) per share, with EPS estimates ranging from ($1.28) to ($0.39). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Adaptimmune Therapeutics PLC.
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last released its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.24). Adaptimmune Therapeutics PLC had a negative return on equity of 28.95% and a negative net margin of 138.46%. The business had revenue of $3.52 million for the quarter, compared to analyst estimates of $5.43 million.
A number of equities analysts have weighed in on ADAP shares. ValuEngine raised Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 20th. Leerink Swann reissued an “outperform” rating and set a $15.00 price target on shares of Adaptimmune Therapeutics PLC in a research report on Friday, September 8th. BidaskClub raised Adaptimmune Therapeutics PLC from a “sell” rating to a “hold” rating in a research report on Friday, August 25th. Zacks Investment Research raised Adaptimmune Therapeutics PLC from a “hold” rating to a “buy” rating and set a $5.25 price target on the stock in a research report on Wednesday, July 12th. Finally, SunTrust Banks, Inc. reissued a “buy” rating and set a $10.00 price target on shares of Adaptimmune Therapeutics PLC in a research report on Thursday, October 12th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $11.58.
Adaptimmune Therapeutics PLC (NASDAQ ADAP) traded up $0.66 on Friday, reaching $8.17. The company had a trading volume of 384,339 shares, compared to its average volume of 260,320.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Alps Advisors Inc. increased its position in Adaptimmune Therapeutics PLC by 4.9% during the second quarter. Alps Advisors Inc. now owns 63,892 shares of the biotechnology company’s stock worth $287,000 after buying an additional 2,996 shares during the last quarter. KCG Holdings Inc. acquired a new position in Adaptimmune Therapeutics PLC during the first quarter worth approximately $133,000. Virtu KCG Holdings LLC increased its position in Adaptimmune Therapeutics PLC by 108.0% during the second quarter. Virtu KCG Holdings LLC now owns 50,279 shares of the biotechnology company’s stock worth $226,000 after buying an additional 26,105 shares during the last quarter. Paloma Partners Management Co acquired a new position in Adaptimmune Therapeutics PLC during the first quarter worth approximately $165,000. Finally, OxFORD Asset Management LLP acquired a new position in Adaptimmune Therapeutics PLC during the second quarter worth approximately $156,000. 68.30% of the stock is currently owned by hedge funds and other institutional investors.
About Adaptimmune Therapeutics PLC
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.